ENTINOSTAT for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 24 adverse event reports in the FDA FAERS database where ENTINOSTAT was used for Renal cell carcinoma.
Most Reported Side Effects for ENTINOSTAT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Infection | 12 | 9.8% | 10 | 0 |
| Anaemia | 11 | 8.9% | 3 | 5 |
| Death | 10 | 8.1% | 10 | 5 |
| Pyrexia | 9 | 7.3% | 4 | 8 |
| Abdominal pain | 8 | 6.5% | 0 | 7 |
| Disease progression | 8 | 6.5% | 8 | 0 |
| Sepsis | 8 | 6.5% | 6 | 5 |
| Thrombocytopenia | 8 | 6.5% | 3 | 2 |
| Fatigue | 7 | 5.7% | 0 | 3 |
| Diarrhoea | 6 | 4.9% | 1 | 4 |
| Febrile neutropenia | 6 | 4.9% | 2 | 3 |
| Hypotension | 6 | 4.9% | 1 | 6 |
| Asthenia | 5 | 4.1% | 0 | 3 |
| Confusional state | 5 | 4.1% | 3 | 4 |
| Dehydration | 5 | 4.1% | 1 | 4 |
Other Indications for ENTINOSTAT
Acute myeloid leukaemia (21)
Breast cancer (16)
Product used for unknown indication (8)
Myelodysplastic syndrome (7)
Adenocarcinoma pancreas (5)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)